Ching Kim Tye
Head of Lipid Nanoparticle & Platform Development Sanofi
Dr. Ching Kim Tye brings two decades of pharmaceutical R&D expertise, specializing in formulation and drug delivery systems. As Head of Drug Product Platform and Early Clinical Development at Sanofi, she leads innovation in mRNA-LNP technology development.
Currently, Kim spearheads the development of next-generation LNPs with enhanced potency and thermostability for both intramuscular and intranasal delivery routes, advancing candidates into Phase 1 clinical trials. Her comprehensive experience spans from early research through late-stage development, including work with diverse therapeutic modalities—proteins and small molecules at CSL, Pfizer, and Eli Lilly.
Seminars
Wednesday 8th April 2026
Panel Discussion: Overcoming Clinical Bottlenecks in LNP Development by Streamlining Processes for Advancing Safer Drug Products to Patients
10:00 am
- What are the greatest technical challenges in translating LNP formulations from preclinic to human studies?
- Given the complexity of LNP manufacturing, scale-up, and analytical characterization, what are the critical process and regulatory bottlenecks that currently slow clinical entry?
- How can developers prioritize indications, optimize clinical trial design, and build CMC readiness to ensure more programs successfully reach patients?
